Trans-ethnic study confirmed independent associations of HLA-A02:06 and HLA-B44:03 with cold medicine-related Stevens-Johnson syndrome with severe ocular surface complications
Stevens-Johnson syndrome (SJS) and its severe variant, toxic epidermal necrolysis (TEN), are acute inflammatory vesiculobullous reactions of the skin and mucous membranes. Cold medicines including non-steroidal anti-inflammatory drugs and multi-ingredient cold medications are reported to be importan...
Saved in:
Published in | Scientific reports Vol. 4; no. 1; p. 5981 |
---|---|
Main Authors | , , , , , , , , , , , , , , , , |
Format | Journal Article |
Language | English |
Published |
London
Nature Publishing Group UK
07.08.2014
Nature Publishing Group |
Subjects | |
Online Access | Get full text |
Cover
Loading…
Summary: | Stevens-Johnson syndrome (SJS) and its severe variant, toxic epidermal necrolysis (TEN), are acute inflammatory vesiculobullous reactions of the skin and mucous membranes. Cold medicines including non-steroidal anti-inflammatory drugs and multi-ingredient cold medications are reported to be important inciting drugs. Recently, we reported that cold medicine related SJS/TEN (CM-SJS/TEN) with severe mucosal involvement including severe ocular surface complications (SOC) is associated with
HLA-A*02:06
and
HLA-B*44:03
in the Japanese. In this study, to determine whether
HLA-B*44:03
is a common risk factor for CM-SJS/TEN with SOC in different ethnic groups we used samples from Indian, Brazilian and Korean patients with CM-SJS/TEN with SOC and investigated the association between CM-SJS/TEN with SOC and
HLA-B*44:03
and/or
HLA-A*02:06
. We found that
HLA-B*44:03
was significantly associated with CM-SJS/TEN with SOC in the Indian and Brazilian but not the Korean population and that
HLA-A*02:06
might be weakly associated in the Korean- but not the Indian and Brazilian population. |
---|---|
Bibliography: | ObjectType-Article-1 SourceType-Scholarly Journals-1 ObjectType-Feature-2 content type line 14 content type line 23 |
ISSN: | 2045-2322 2045-2322 |
DOI: | 10.1038/srep05981 |